EC

Ecopetrol SA ADR
NYSEENERGYOIL & GAS INTEGRATED

Key Statistics

Market Cap
$30.20B
P/E Ratio
10.49
EPS
$1.40
Beta
-0.01
52W High
$17.75
52W Low
$7.88
50-Day MA
$14.59
200-Day MA
$12.11
Dividend Yield
4.42%
Profit Margin
7.52%
Forward P/E
9.12
PEG Ratio
0.77

About Ecopetrol SA ADR

Ecopetrol SA is an integrated oil and gas company. The company is headquartered in Bogot, Colombia.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$125.67T
Gross Profit (TTM)$41.19T
EBITDA$43.17T
Operating Margin0.00%
Return on Equity12.00%
Return on Assets5.67%
Revenue/Share (TTM)$30563.47
Book Value$1963.05
Price-to-Book1.32
Price-to-Sales (TTM)0.92
EV/Revenue1.702
EV/EBITDA7.10
Quarterly Earnings Growth (YoY)-7.70%
Quarterly Revenue Growth (YoY)-8.70%
Shares Outstanding$2.06B
Float$473.17M
% Insiders0.00%
% Institutions1.32%

Historical Volatility

HV 10-Day
42.93%
HV 20-Day
48.18%
HV 30-Day
55.84%
HV 60-Day
49.54%
HV Rank
98.0%

Volatility is currently contracting

Analyst Ratings

Consensus ($13.35 target)
7
Hold
3
Sell
1
Strong Sell

Latest News

Ecopetrol Group receives payment for 100% of the FEPC account receivable balance for the second quarter of 2025

BOGOTÁ, Colombia, July 1, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL) (NYSE: EC) (the "Company") hereby announces that the National Government, through Resolution 1492 dated June 30, 2026, issued by the Ministry of Finance and Public Credit ("MHCP"), recognized and ordered payment to the Ecopetrol Group in an aggregate amount of approximately COP 1 trillion, corresponding to the account receivable from the Fuel Price Stabilization Fund ("FEPC") for the second quarter of 2025.

PRNewsWire7/1/2026Neutral
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas 2,3 NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.

PRNewsWire6/23/2026Neutral

More ENERGY Stocks

Data last updated: 7/9/2026